HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stevia studied

This article was originally published in The Tan Sheet

Executive Summary

Coca-Cola and Cargill say research published in the Food and Chemical Toxicology journal May 15 "clearly establishes the safety of rebiana," the common name for high-purity Rebaudioside A, derived from the stevia plant, to be used as a natural sweetener for beverages and foods. The firms partnered last year and developed rebiana as a natural, calorie-free ingredient and plan to market it as Truvia under Cargill (1"The Tan Sheet" June 11, 2007, p. 14). Stevia is sold in the U.S. today as a dietary supplement, but is not approved in the country for use in food because of a lack of safety data, according to a May 15 release...

You may also be interested in...



Wisdom’s Unconventional Launch: Stevia Sweetener Without FDA’s GRAS

Wisdom Natural Brands launches a natural sweetener formulation derived from the stevia leaf without FDA affirming the ingredient as safe, an approach industry stakeholders say is best for the firm's business

Coca-Cola, Cargill Partner To Create Stevia-Sweetened Beverage

Coca-Cola and Cargill are partnering to bring a stevia-sweetened beverage to market in nine to 18 months, a Cargill spokesperson said June 5

Despite ‘Almost Nonexistent’ Cough/Cold Season, Perrigo's 2020 Consumer Health Sales Grow 6%

Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.

Topics

UsernamePublicRestriction

Register

LL1134561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel